Connor Clark & Lunn Investment Management Ltd. Raises Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Connor Clark & Lunn Investment Management Ltd. grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 220,801 shares of the pharmaceutical company’s stock after purchasing an additional 14,706 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Vertex Pharmaceuticals were worth $86,475,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Chesapeake Asset Management LLC grew its stake in Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 33 shares during the last quarter. Colonial Trust Co SC raised its stake in Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 38 shares during the last quarter. Total Investment Management Inc. purchased a new stake in Vertex Pharmaceuticals in the second quarter valued at about $33,000. Financial Network Wealth Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 50.9% in the third quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after acquiring an additional 29 shares in the last quarter. Finally, Y.D. More Investments Ltd grew its stake in shares of Vertex Pharmaceuticals by 345.0% during the third quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock worth $35,000 after acquiring an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.4%

Vertex Pharmaceuticals stock opened at $492.38 on Thursday. The stock has a 50-day moving average price of $469.19 and a 200 day moving average price of $436.92. The company has a market capitalization of $125.08 billion, a price-to-earnings ratio of 32.12 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same quarter last year, the company posted $3.98 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER data for povetacicept showed a large (~52%) reduction in proteinuria in IgA nephropathy, boosting hopes for an expedited regulatory filing and expansion of Vertex into kidney disease — a clear fundamental catalyst. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Positive Sentiment: Multiple banks raised price targets and reiterated Buy/Outperform ratings after the trial (Morgan Stanley, BofA, Oppenheimer, Citigroup, HC Wainwright, Truist, Jefferies, etc.), increasing analyst upside and supporting further gains. Analyst price target coverage roundup
• Positive Sentiment: Broker commentary and coverage upgrades (e.g., new coverage from Jefferies, maintained/raised ratings at BMO and others) reinforce investor confidence in povetacicept’s commercial potential and Vertex’s pipeline diversification. BMO Capital sticks to Buy rating
• Neutral Sentiment: Company presentations at healthcare conferences (Barclays, Leerink transcripts published) provide management commentary and additional detail for investors, but contain no new trial data beyond the RAINIER release. Barclays conference transcript
• Neutral Sentiment: Coverage in market media noted Vertex’s rising biotech weight in Nasdaq indices and broader attention following the trial — visibility that can attract flows but also raise short‑term trading interest. Biotech focus rises in Nasdaq index
• Negative Sentiment: After the big rally, the stock is pulling back (broader coverage flagged a larger intraday fall vs. the market); this looks like classic profit‑taking/mean reversion after rapid gains, increasing short‑term volatility risk. Vertex registers a bigger fall than the market
• Negative Sentiment: Zacks and other outlets also noted that recent earnings estimate revision trends and any lingering execution questions could temper momentum, so some analysts caution that the upside may be paced by upcoming filings and commercialization visibility. Will this strength last?

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 4,910 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the sale, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. This trade represents a 21.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jonathan Biller sold 945 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $459,600.75. Following the completion of the sale, the executive vice president owned 13,659 shares in the company, valued at $6,643,054.65. The trade was a 6.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 91,156 shares of company stock valued at $42,845,497 in the last 90 days. 0.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on VRTX. Royal Bank Of Canada cut their price objective on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a report on Friday, February 13th. Leerink Partners boosted their target price on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research report on Monday, December 29th. Truist Financial upped their price target on shares of Vertex Pharmaceuticals from $490.00 to $525.00 and gave the company a “buy” rating in a research note on Wednesday. Oppenheimer raised their price target on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Canaccord Genuity Group lifted their price objective on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research note on Tuesday, February 17th. Twenty-three investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $553.36.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.